Key Financial Highlights: Full-year net sales increased to €21.2 billion (organically: +2.0%) EBITDA pre rose to €6.1 billion (orga...
The Global Health Innovative Technology (GHIT) Fund is announcing a significant milestone: the first administration of arpraziquantel to preschool-aged chi...
The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed ...
Miltenyi Biotec, a global leader in cell and gene therapy solutions, has inaugurated a cutting-edge Cell & Gene Therapy Center in Genome Valley...
Philadelphia has long been known as a hub for history, education, and culture. But in recent years, the city has also solidified itself as a powerhouse i...
Appointment of three internal senior executives ensures strategic continuity with a new era of leadership Jean-Charles Wirth to become CEO Life Scienc...
Artificial intelligence is reshaping oncology, and ImpriMed is at the forefront of this transformation. With its AI-powered Personalized Prediction Profi...
AstraZeneca delivered $54.1 billion in total revenue for FY 2024, a 21% increase at constant exchange rates (CER), fueled by strong growth across oncolog...
Intuitive BioTechnologies LLC (IBT) is proud to announce they have added elemental analysis to their testing capabilities. IBT is now offering quantitati...
Illumina, led by CEO Jacob Thaysen, delivered a Q4 revenue of $1.1 billion, reflecting a steady 1% year-over-year increase, w...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced its financial results for the first quarter ...
The research of BioMed X team EDC - Extrachromosomal DNA in Cancer - has uncovered critical insights into the mechanisms driving extrachromosomal ...
Pfizer Inc. reported robust financial results for the full year 2024, achieving total revenues of $63.6 billion, reflecting a 7% year-over-year operation...
Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from Ent...
© 2025 Biopharma Boardroom. All Rights Reserved.
